Indications for Dasanix 20 mg:
Dasanix 20 mg is recommended for adults with:

– Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
– Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
– Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

Therapeutic Class:
Targeted Cancer Therapy

Pharmacology:
Dasanix 20 mg inhibits various kinases, including BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ, at nanomolar concentrations. It is predicted to bind to multiple conformations of the ABL kinase. In vitro studies demonstrate its effectiveness against leukemic cell lines, including those resistant to imatinib. Dasanix 20 mg has shown inhibitory effects on the growth of CML and ALL cell lines overexpressing BCR-ABL, even in cases of imatinib resistance.

Dosage & Administration of Dasanix 20 mg:
The recommended starting dosage varies depending on the phase of CML or ALL:
– Chronic phase CML: 100 mg orally once daily.
– Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL: 140 mg orally once daily. Tablets should be swallowed whole, with or without food, either in the morning or evening. Treatment with Dasanix 20 mg is typically continued until disease progression or intolerance, but the long-term effects after achieving a cytogenetic or molecular response are not fully understood.

Interaction of Dasanix 20 mg:
Avoid concomitant use with drugs that may interact with Dasanix 20 mg, such as CYP3A4 inhibitors or inducers, and antacids. Increased risk of bleeding and thrombocytopenia when used with certain medications.

Contraindications:
Avoid use with CYP3A4 inhibitors, inducers, or antacids, and during pregnancy.

Side Effects of Dasanix 20 mg:
Common adverse reactions include myelosuppression, fluid retention, pulmonary arterial hypertension, QT prolongation, cardiac issues, hypertension, GI disturbances, headache, fatigue, musculoskeletal pain, rash, and dermatitis, among others.

Pregnancy & Lactation:
Category D drug, with evidence of fetal risk. Use in pregnant women may be warranted in certain situations, despite potential risks.

Precautions & Warnings:
Special caution is advised in patients with predisposing factors for QT prolongation, hepatic impairment, and during lactation. Monitor closely for myelosuppression in cases of overdose.

Storage Conditions:
Dasanix 20 mg tablets should be stored at room temperature (20°C to 25°C).

Use in Special Populations:
Safety and efficacy in pediatric patients (<18 years) have not been established. Geriatric patients may experience similar adverse reactions but should be monitored closely. No dosage adjustment is needed in patients with hepatic impairment, while data is limited for those with renal impairment.